Careful approaches are needed over biosimilar business

The government will need to work out measures to push up with the controversial biosimilar business in more cautious manner, experts claimed.

They argued that generic drug companies are ready to make cheaper versions of some of the biotech industry’s best sellers, the process for making biologics is more complex and risky than for traditional pharmaceuticals.

That leaves biosimilars with ...